(Adnkronos) - Ridefinire radicalmente il trattamento delle maculopatie in Italia. L’introduzione di aflibercept 8 mg, una nuova formulazione rispetto ai 2 mg della precedente, rappresenta un progresso nella cura della degenerazione maculare neovascolare (nAmd) e dell’edema maculare diabetico (Dme) perché riduce il numero di iniezioni intravitreali che da mensili diventano ogni 5 e, addirittura, in alcuni pazienti, ogni 6 mesi. A migliorare la qualità di vita dei pazienti e a semplificare l’attività clinica c’è anche il lancio in Italia di OcuClick™, una siringa pre-riempita per la somministrazione di aflibercept 8 mg, come si è evidenziato nell’ incontro con la stampa ‘Una nuova opportunità per la gestione della maculopatia’, organizzato da Bayer a Milano.
Category
🗞
NewsTranscript
00:00There are over a million patients in Italy affected by maculopathy, the set of pathologies
00:09that affects the macula, the central area of the retina, with an important impact on
00:13the visual ability.
00:14The introduction of Aflibercept OTMG, a new formulation of Aflibercept recently adopted
00:19in Italy, represents an important progress in the treatment of neovascular macular degeneration
00:25and diabetic macular edema, since it allows to go from the monthly cadence injection
00:30of the drug, as was the case with the formulation of 2 mg previously used, to 8
00:35supplements in two years.
00:37Aflibercept OTMG, tested in two pivotal studies, PULSAR and PHOTON, macular degeneration
00:43linked to age, the first of neovascular type and diabetic macular edema, the second study,
00:50these studies have shown the therapeutic equivalence between the old Aflibercept 2 mg and the new
00:58drug, but above all a significant reduction of the number of treatments necessary to
01:04one year, two years and three years from the start of the treatment.
01:09The reduction of the number of injections necessary favors greater therapeutic adherence
01:13and contributes to lighten the load on the health system.
01:17Looking to the future, the idea of being able to have drugs that last in the eye for
01:22three months, four, even five, six, after the dose of load, means being able to reduce
01:27in such a substantial way the number of procedures that the adherence to therapy can improve
01:33a lot and consequently also the effectiveness of therapy and therefore with enormous advantages
01:38from a clinical point of view.
01:40It greatly improves the possibility for the structures to be able to guarantee an adequate
01:47management of problems and then it means to have enormous advantages from the point of
01:52view of costs, because the health system at that point, with a figure that is equal to
01:57the previous one, can achieve enormously better results.
02:00The positive impact of this approach is not limited to guaranteeing an effective management
02:04of the disease, but significantly improves the quality of life of patients and their
02:08caregivers.
02:09This drug allows a distance of even five months.
02:13Well, this means a lot for the patient, to be well, to see well, not to have and not to experience
02:25the frequency of the injection violence, it also means not to have the side effects
02:32of the injection, because, forgive me, one count is to do 12, one count is to do 2,
02:39the lower the number, the lower the statistic of bad luck or adverse event.
02:45It is also recent the launch in Italy of OcuClick, a syringe pre-filled for the supply
02:50of Afflivercept 8 mg, designed to simplify and further optimize the therapeutic management
02:56of these important eye conditions.
02:59This further innovation is also the result of the important commitment of Bayer in Nostalmology.
03:04Bayer has a great commitment to improve the lives of people and, above all, today
03:12we are here to talk about our commitment to improve the sight, which is one of the most
03:16important organs.
03:17To see means to live better.